Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Appili Therapeutics Inc T.APLI

Alternate Symbol(s):  APLIF

Healthcare Biotechnology
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSX:APLI)

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

GlobeNewswire March 30, 2026

Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement

GlobeNewswire February 18, 2026

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026

GlobeNewswire February 12, 2026

Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

GlobeNewswire December 18, 2025

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026

GlobeNewswire November 13, 2025

Appili Therapeutics Announces Proposed Non-Brokered Private Placement

GlobeNewswire November 5, 2025

Appili Therapeutics to Attend BARDA Innovation Symposium 2025

GlobeNewswire October 22, 2025

Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01

GlobeNewswire October 1, 2025

Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

GlobeNewswire September 23, 2025
View More News ››

Opinion & Analysis (TSX:APLI)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSX:APLI)

Appili Therapeutics and its Partner Vitalex Biosciences

Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01 https://stockhouse.com/news/press-releases...
opsd1 - October 20, 2025

New contract worth up to 10 times current market cap!

Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal...
opsd1 - October 2, 2025

Those who have asks at 0.04 are probably not aware of

today's news release. I doubt they'll be there for long.
opsd1 - October 1, 2025

Appili Therapeutics and its Partner Vitalex Biosciences

Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01 https://stockhouse.com/news/press-releases...
opsd1 - October 1, 2025

RE:New shareholder.

I'm curious. Do you still think this one will gain value in the near future?
MrBinks - August 18, 2024

Appili Therapeutics Sign Definitive Agreement to be Acquired

Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced...
Betteryear2 - April 2, 2024
View more Bullboard ››

Cannabix Technologies Inc.

Cannabix Technologies Inc.

Cannabix Technologies Inc., a technology company, develops marijuana and alcohol breathalyzer technologies for employers, law ...
View More »

Podcasts